Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16417903 | 0.87 | KDM4C (0.39) | MC4RMEN1KMT2ACA1CA12 | |
| SCHEMBL25567933 | 0.86 | ALDH1A1 (0.34) | MEN1KMT2ACA1CA12CA2 | |
| SCHEMBL27014703 | 0.86 | CA1 (0.43) | CA1CA12CA2CA9ALDH1A1 | |
| SCHEMBL12763774 | 0.83 | CA12 (0.45) | MC4RMEN1KMT2ACA1CA12 | |
| SCHEMBL304558 | 0.82 | MEN1 (0.33) | MEN1KMT2ACA1CA12CA2 | |
| SCHEMBL7603535 | 0.82 | ALDH1A1 (0.34) | MEN1KMT2ACA1CA12CA2 | |
| SCHEMBL13301217 | 0.81 | TSHR (0.37) | MEN1KMT2ACA1CA12CA2 | |
| SCHEMBL16125928 | 0.79 | CA14 (0.39) | MEN1KMT2ACA1CA12CA2 | |
| SCHEMBL304323 | 0.79 | MEN1 (0.32) | MEN1KMT2ACA1CA12CA2 | |
| SCHEMBL6201216 | 0.79 | CA12 (0.44) | MC4RMEN1KMT2ACA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | claimed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | claimed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | claimed |
| WO-2022081995-A1 | MALT1 MODULATORS AND USES THEREOF | RHEOS MEDICINES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-2415875-B1 | METHOD FOR IDENTIFICATION OF METALLO-[BETA]-LACTAMASE-PRODUCING BACTERIUM | MEIJI SEIKA PHARMA CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8697382-B2 | Method of identifying metallo-β-lactamase-producing bacteria | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-04-15 | — | — | US | disclosed |
| US-8344154-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120064557-A1 | METHOD OF IDENTIFYING METALLO-BETA-LACTAMASE-PRODUCING BACTERIA | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| EP-2415875-A1 | METHOD FOR IDENTIFICATION OF METALLO- B -LACTAMASE-PRODUCING BACTERIUM | Meiji Seika Pharma Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MARUYAMA TAKAHISA | 2010-06-10 | — | — | US | disclosed |
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | MC4R 4765/4885MEN1 332/4885KMT2A 1979/4885 |
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, TPMT | MC4R 3299/4885MEN1 3301/4885KMT2A 1498/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | MC4R 4765/4885MEN1 332/4885KMT2A 1979/4885 |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | MC4R 4088/4885MEN1 2685/4885KMT2A 351/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | MC4R 4768/4885MEN1 339/4885KMT2A 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.